长高电新科技股份公司（以下简称"公司"）于 2025 年 8 月 14 日收到深圳 证券交易所（以下简称"深交所"）出具的《关于受理长高电新科技股份公司向 不特定对象发行可转换公司债券申请文件的通知》（深证上审〔2025〕150 号）。 深交所对公司报送的向不特定对象发行可转换公司债券的申请文件进行了核对， 认为申请文件齐备，决定予以受理。 公司本次向不特定对象发行可转换公司债券事项尚需深交所审核，并获得中 国证券监督管理委员会（以下简称"证监会"）作出同意注册的批复后方可实施， 最终能否通过深交所审核并获得证监会作出同意注册的批复及其时间尚存在不确 定性。 公司将根据该事项的进展情况，按照相关法律法规规定和要求及时履行信息 披露义务，敬请广大投资者注意投资风险。 特此公告。 证券代码：002452 证券简称：长高电新 公告编号：2025-34 长高电新科技股份公司 关于向不特定对象发行可转换公司债券申请获得 深圳证券交易所受理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 长高电新科技股份公司董事会 ...

Group 1 - The company will pay the third-year interest on the "Tianjian Convertible Bonds" on August 22, 2025, at a rate of 4.00 CNY per 10 bonds (including tax) [2][12] - The bond's interest rates are structured as follows: 0.2% for the first year, 0.3% for the second year, 0.4% for the third year, 1.5% for the fourth year, 1.8% for the fifth year, and 2.0% for the sixth year [3][11] - The total issuance of the "Tianjian Convertible Bonds" is 4,950,000 bonds, with a total value of 49.5 million CNY [5][11] Group 2 - The bond's interest payment dates are as follows: the record date is August 21, 2025, the ex-dividend date is August 22, 2025, and the payment date is also August 22, 2025 [14][15] - The company will utilize China Securities Depository and Clearing Corporation Limited Shenzhen Branch for the interest payment process [16] - The bonds have a credit rating of AA+ from Dongfang Jincheng International Credit Evaluation Co., Ltd., with a stable outlook [11]

| 证券投 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 资基金 | | | | | | | | 香港中 | | | | | | | | 央结算 | 境外法 | | | | | | | 有限公 | 人 | | | | | | | 司 | | | | | | | | 境内自 | | | | | | | | 许颇 | | 1.16% | 4,612,984 | | 不适用 | | | 然人 | | | | | | | | 中国农 | | | | | | | | 业银行 | | | | | | | | 0.89% | 其他 | | 3,537,243 | | 不适用 | | | 股份有 | | | | | | | | 限公司 | | | | | | | | | | | | | 锦浪科技股份有限公司 | 2025 年半年度报 | | 告摘要 | | | | | | | | －中证 | | | | | | | | 型开放 | | | | | | | | 式指数 | | | | | | | | 证券投 | | | | | | | | 资基金 | | ...

Core Viewpoint - Sanxin Medical (300453) announced on August 14 that it plans to expand its R&D and production base in Jiangxi to meet the growing market demand for blood dialysis products and to reserve new capacity for rapid expansion in new business areas such as vascular intervention [1] Group 1: Company Expansion Plans - The company aims to expand its production lines and procure raw materials to meet increasing working capital needs [1] - The expansion will support the annual production of 10 million blood dialysis membranes and 10 million blood dialysis devices [1] - New projects include the establishment of a production line for 30 million sets of high-performance blood purification equipment and supporting consumables [1] Group 2: Financing Strategy - The company plans to issue convertible bonds to raise no more than 530 million yuan, which will enhance its financial strength and optimize its asset structure [1] - The funds will be used for the expansion projects and to supplement working capital, thereby improving financial flexibility and reducing operational risks [1]

Core Viewpoint - The report outlines the issuance of convertible bonds by Puyang Puna High Temperature Materials (Group) Co., Ltd., detailing the approval process, terms, and current status of the bonds [2][3][4]. Summary by Sections Issuance Approval - The issuance plan for the convertible bonds was approved by the company's board on April 17, 2020, and subsequently by the shareholders on May 7, 2020 [2]. - The application for the public issuance was approved by the China Securities Regulatory Commission (CSRC) on November 23, 2020 [3]. Bond Details - The total face value of the convertible bonds issued is RMB 626,390,300, with a net amount raised of RMB 617,648,279.22 after deducting issuance costs [4]. - The bonds have a term of 5 years, from May 26, 2021, to May 25, 2026 [5]. Key Terms of the Bonds - The bonds are convertible into A-shares of the company, with an initial conversion price set at RMB 4.43 per share [6][19]. - The bonds will pay interest annually, with rates of 0.6% for the first year, 0.8% for the second year, and 1.0% for the third year [6]. Conversion and Redemption - The conversion period for the bonds is from December 1, 2021, to May 25, 2026 [19]. - As of August 6, 2025, a total of 105,082,078 shares have been converted, representing 10.40% of the company's total shares prior to the bond issuance [18][21]. Current Status and Adjustments - The latest conversion price has been adjusted to RMB 4.20 per share as of July 11, 2025, following previous adjustments [20]. - There are still 1,845,752 bonds unconverted, which is 29.47% of the total issued bonds [21]. Fund Utilization - The funds raised will be allocated to specific projects, including the intelligent manufacturing of refractory materials and high-performance environmental protection products [16][17]. Management and Oversight - Guotai Junan Securities serves as the trustee manager for the bonds, ensuring the protection of bondholders' rights and interests [2][21].

Group 1 - The company, Ningbo Sinyuan Zm Technology Co., Ltd., is engaged in the research, production, and sales of magnesium alloy and aluminum alloy precision die-casting products, primarily for the automotive industry [4][6][25] - The company has established a strong market position as a pioneer in the magnesium alloy die-casting sector, focusing on the large-scale application of magnesium alloys in automotive lightweighting [6][12] - The company’s main products include components for automotive display systems, seats, new energy vehicle powertrains, and other automotive parts, with notable clients including Audi, Ford, and Hongqi [6][7][25] Group 2 - The company reported a total revenue of 40,860.44 million yuan for the year 2024, with a net profit of 8,033.11 million yuan, indicating a growth trend in its financial performance [8][9] - The company’s total assets reached 125,177.61 million yuan, with total liabilities of 14,519.39 million yuan, reflecting a solid financial foundation [9][10] - The company’s gross profit margin has shown a declining trend, influenced by increased market competition and customer pricing pressures [15][16] Group 3 - The company plans to raise up to 45,000 million yuan through the issuance of convertible bonds to fund projects aimed at enhancing its production capacity for high-strength magnesium alloy components [36] - The proposed investment projects are expected to significantly increase the company’s market supply capability and core competitiveness in the automotive parts sector [12][15] - The company’s strategic focus includes continuous innovation and technology improvement to meet the evolving demands of the automotive industry [23][24]

Core Viewpoint - Ningbo Xingyuan Zhuomei Technology Co., Ltd. is responding to the inquiry letter regarding its application for issuing convertible bonds, providing detailed explanations on various financial metrics and operational strategies. Financial Performance - The company's main business revenue for the reporting periods was 214.68 million, 265.98 million, 171.15 million, 53.23 million, and 55.12 million, with net profits of 53.65 million and a growth rate of 30.98% [1]. - The company's inventory values at the end of each reporting period were 49.93 million, 62.45 million, and 71.77 million, with an asset-liability ratio of 7.88% as of September 30, 2024 [1]. Cash Flow Analysis - The net cash flow from operating activities was consistently lower than net profit, with discrepancies attributed to inventory changes and non-cash expenses [2][3]. - The company experienced a significant increase in accounts receivable, impacting cash flow negatively, particularly in 2022 [2]. Gross Margin Fluctuations - The fluctuation in gross margin was influenced by the prices of magnesium and aluminum alloy raw materials, with sensitivity analysis indicating that a 10% change in raw material prices could affect gross margins by approximately 2.04% to 2.85% [4][5]. - The gross margin for magnesium alloy die-casting products was significantly affected by raw material price increases, leading to a decrease in profitability in 2022 [3][4]. Pricing Mechanisms - The company employs a pricing strategy based on cost-plus and market quotations, with adjustments made for raw material price fluctuations and other factors [6][7]. - There are annual price reduction clauses in place for certain products, with reductions ranging from 10.19% to 35.87% over the years [8][9]. Competitive Position - Compared to industry peers, the company's gross margin for die-casting products remains higher, attributed to its focus on magnesium alloy products and a smaller competitive landscape [4][5]. - The company has maintained a competitive edge in the magnesium alloy sector due to its long-standing expertise and strategic partnerships with suppliers [6][7]. Risk Management Strategies - The company has implemented measures to mitigate the impact of raw material price volatility, including optimizing inventory management and establishing strategic supplier relationships [5][6]. - Specific pricing adjustment mechanisms are in place to address significant fluctuations in raw material costs, ensuring that the company can maintain profitability [10].

Core Points - The company announced an adjustment to the conversion price of its convertible bonds based on the 2024 profit distribution plan, reducing the price from 16.09 CNY to 15.92 CNY per share [2][5] - The adjustment will take effect on August 20, 2025, following the company's cash dividend distribution of 1.70 CNY per 10 shares [3][5] Summary of Convertible Bonds - The company issued 85 million convertible bonds with a face value of 100 CNY each, raising a total of 850 million CNY, netting 847.875 million CNY after deducting issuance costs [2] - The initial conversion price was set at 16.09 CNY per share, with the conversion period starting six months after the issuance [2] Basis for Conversion Price Adjustment - The adjustment is based on the company's profit distribution plan approved at the third extraordinary general meeting on July 1, 2025, which includes a cash dividend of 1.70 CNY per 10 shares [3][4] - The adjusted conversion price formula is P1 = P0 - D, where D is the cash dividend per share [4] Results of Conversion Price Adjustment - The adjusted conversion price is calculated to be approximately 15.92 CNY per share, effective from the ex-dividend date of August 20, 2025 [5] - The cash dividend per share, after considering the total share capital, is approximately 0.1685 CNY [5][9] Profit Distribution Plan - The profit distribution plan for the fiscal year 2024 includes a cash dividend of 0.17 CNY per share, totaling approximately 2.017 billion CNY [7][9] - The distribution will be made to all shareholders registered by the close of trading on August 19, 2025 [8] Tax Implications - For individual shareholders, the cash dividend will not be subject to withholding tax at the time of distribution, with tax calculated based on the holding period upon sale of shares [13] - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net cash dividend of 0.153 CNY per share [14]

Core Viewpoint - Sanxin Medical announced on August 13 that it is expanding its operational scale and increasing its demand for working capital due to the growth in the medical device industry [2] Group 1: Company Overview - Sanxin Medical has a strong foundation in the medical device industry, leading to continuous expansion of its operational scale [2] - The company plans to issue convertible bonds to enhance its financial strength and optimize its asset structure [2] Group 2: Financial Strategy - The company aims to raise no more than 530 million yuan through the issuance of convertible bonds, which will be used for various projects and to supplement working capital [2] - The funds will specifically support the expansion of production lines for blood dialysis membranes and devices, as well as the establishment of a new production line for blood dialysis tubing [2]

股票简称：新化股份 股票代码：603867 债券简称：新化转债 债券代码：113663 一、核准文件及核准规模 经中国证券监督管理委员会《关于核准浙江新化化工股份有限公司公开发行 可转换公司债券的批复》（证监许可[2022]2163号）批准，公司向社会公开发行 可转换公司债券6,500,000张，每张面值人民币100元，募集资金总额为65,000.00 万元，扣除发行费用后募集资金净额为人民币63,925.33万元。上述募集资金已 于2022年12月2日到位，业经天健会计师事务所（特殊普通合伙）验证，并出具 了天健验[2022]660号《验证报告》。 经上海证券交易所同意，公司本次发行的可转债于2022年12月16日起在上 海证券交易所挂牌交易，债券简称"新化转债"，债券代码"113663"。 二、本次债券的主要条款 浙江新化化工股份有限公司 公开发行可转换公司债券 临时受托管理事务报告 债券受托管理人 二零二五年八月 重要声明 （一）发行证券的种类 本报告依据《可转换公司债券管理办法》（以下简称"《管理办法》"）、《浙 江新化化工股份有限公司关于向不特定对象发行可转换公司债券之受托管理协 议》（以下简称"《 ...